

This is a repository copy of *Derivation and external validation of risk algorithms for cerebrovascular (re)hospitalisation in patients with type 2 diabetes: Two cohorts study.* 

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/153485/

Version: Accepted Version

# Article:

Yu, D., Cai, Y., Graffy, J. et al. (3 more authors) (2018) Derivation and external validation of risk algorithms for cerebrovascular (re)hospitalisation in patients with type 2 diabetes: Two cohorts study. Diabetes Research and Clinical Practice, 144. pp. 74-81. ISSN 0168-8227

https://doi.org/10.1016/j.diabres.2018.08.006

Article available under the terms of the CC-BY-NC-ND licence (https://creativecommons.org/licenses/by-nc-nd/4.0/).

#### Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: https://creativecommons.org/licenses/

### Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



- 1 Title: Derivation and external validation of risk algorithms for cerebrovascular
- 2 (re)hospitalisation in patients with type 2 diabetes: two cohorts study
- 3
- Authors: Dahai Yu<sup>1,2</sup>, Yamei Cai<sup>1</sup>, Jonathan Graffy<sup>3</sup>, Daniel Holman<sup>4</sup>, Zhanzheng Zhao<sup>1</sup>, David
   Simmons<sup>5</sup>
- 6 1Department of Nephrology, the First Affiliated Hospital, Zhengzhou University,
- 7 Zhengzhou 450052, China.
- 8 2Arthritis Research UK Primary Care Centre, Research Institute for Primary Care & Health
- 9 Sciences, Keele University, Keele ST5 5BG, UK.
- 10 3Primary Care Unit, Department of Public Health and Primary Care, University of 11 Cambridge, Cambridge, Cambridgeshire CB2 oSR, United Kingdom
- 12 4Department of Sociological Studies, University of Sheffield, Sheffield S10 2TU, United
- 13 Kingdom
- 14 5Western Sydney University, Campbelltown, Sydney NSW 2760, Australia
- 15
- 16 Correspondence: Zhanzheng Zhao
- 17 Department of Nephrology
- 18 the First Affiliated Hospital, Zhengzhou University
- 19 Zhengzhou 450052, CHINA
- 20 Tel +86 139 3852 5666
- 21 Fax +86 371 6698 8753
- 22 Email zhanzhengzhao@zzu.edu.cn
- 2324 Correspondence: David Simmons
- 25 Macarthur Clinical School
- 26 School of Medicine, Western Sydney University
- 27 Locked Bag 1797, Campbelltown NSW 2760, AUSTRALIA
- 28 Tel (61+2) 4620 3899
- 29 Fax (61+2) 4620 3890
- 30 Email dsworkster@gmail.com
- 31
- 32 Word count: 2,953 words
- Short title: Risk score for CeV (re)hospitalisation in T2DM
  Short title: Risk score for CeV (re)hospitalisation in T2DM
  Short title: Risk score for CeV (re)hospitalisation in T2DM
  Short title: Risk score for CeV (re)hospitalisation in T2DM
  Short title: Risk score for CeV (re)hospitalisation in T2DM
  Short title: Risk score for CeV (re)hospitalisation in T2DM
  Short title: Risk score for CeV (re)hospitalisation in T2DM
  Short title: Risk score for CeV (re)hospitalisation in T2DM
  Short title: Risk score for CeV (re)hospitalisation in T2DM
  Short title: Risk score for CeV (re)hospitalisation in T2DM
  Short title: Risk score for CeV (re)hospitalisation in T2DM
  Short title: Risk score for CeV (re)hospitalisation in T2DM
  Short title: Risk score for CeV (re)hospitalisation in T2DM
  Short title: Risk score for CeV (re)hospitalisation in T2DM
  Short title: Risk score for CeV (re)hospitalisation in T2DM
  Short title: Risk score for CeV (re)hospitalisation in T2DM
  Short title: Risk score for CeV (re)hospitalisation in T2DM
  Short title: Risk score for CeV (re)hospitalisation in T2DM
  Short title: Risk score for CeV (re)hospitalisation in T2DM
  Short title: Risk score for CeV (re)hospitalisation in T2DM
  Short title: Risk score for CeV (re)hospitalisation in T2DM
  Short title: Risk score for CeV (re)hospitalisation in T2DM
  Short title: Risk score for CeV (re)hospitalisation in T2DM
  Short title: Risk score for CeV (re)hospitalisation in T2DM
  Short title: Risk score for CeV (re)hospitalisation in T2DM
  Short title: Risk score for CeV (re)hospitalisation in T2DM
  Short title: Risk score for CeV (re)hospitalisation in T2DM
  Short title: Risk score for CeV (re)hospitalisation in T2DM
  Short title: Risk score for CeV (re)hospitalisation in T2DM
  - 1

- 43 ABSTRACT
- 44

45 **Aims:** Cerebrovascular disease is one of more typical reasons for hospitalisation and re-

46 hospitalisation in people with type 2 diabetes. We aimed to derive and externally validate two risk

47 prediction algorithms for cerebrovascular hospitalisation and re-hospitalisation.

48 Methods: Two independent cohorts were used to derive and externally validate the two risk

49 scores. The development cohort comprises 4,704 patients with type 2 diabetes registered in 18

50 general practices across Cambridgeshire. The validation cohort includes 1,121 type 2 patients from

a post-trial cohort data. Outcomes were cerebrovascular hospitalisation within two years and

52 cerebrovascular re-hospitalisation within ninety days of the previous cerebrovascular

53 hospitalisation. Logistic regression was applied to derive the two risk scores for cerebrovascular

54 hospitalisation and re-hospitalisation from development cohort, which were externally validated

55 in the validation cohort.

56 **Results:** The incidence of cerebrovascular hospitalisation and re-hospitalisation was 3.76% and

57 1.46% in the development cohort, and 4.99% and 1.87% in the external validation cohort. Age,

58 gender, body mass index, blood pressures, and lipid profiles were included in the final model.

59 Model discrimination was similar in both cohorts, with all C-statistics > 0.70, and very good

60 calibration of observed and predicted individual risks.

61 Conclusion: Two new risk scores that quantify individual risks of cerebrovascular hospitalisation
62 and re-hospitalisation have been well derived and externally validated. Both scores are on the
63 basis of a few of clinical measurements that are commonly available for patients with type 2
64 diabetes in primary care settings and could work as tools to identify individuals at high risk of
65 cerebrovascular hospitalisation and re-hospitalisation.

66

67 Keywords: Cerebrovascular disease; Diabetes population; Risk prediction; Primary care
68

69

#### 71 INTRODUCTION

Type 2 Diabetes as a risk factor for cerebrovascular diseases has been found to be markedly associated with increased risk of cerebrovascular mortality. One meta-analysis revealed that in comparison with people without diabetes, people with diabetes had a 2.27-fold of increased risk of cerebrovascular disease [1]. As cerebrovascular disease is one of the major causes of death and disability in people with type 2 diabetes [2], risk algorithms to predict cerebrovascular disease have been increasingly developed to facilitate the effective management of high risk individuals [3].

79

80 It is common for people with diabetes to be admitted to hospital, with one in five inpatients having diabetes in some age groups in England [4]. Cerebrovascular diseases is one of the more 81 82 common causes for hospitalisation in patients with type 2 diabetes [5]. And it is also common for patients with type 2 diabetes to be re-hospitalised for cardiovascular or cerebrovascular disease 83 84 [6]. The associated increased inpatient costs are marked factors to the health burden borne by 85 heath care system as a result of diabetes and often reflects manageable morbidities suffered by patients with diabetes. A prediction tool to identify individuals at particularly high risk of 86 87 cerebrovascular hospitalisation and re-hospitalisation would facilitate subsequent more intensive 88 interventions.

89

A systematic review identified 12 risk scores to predict coronary heart or cerebrovascular disease
conducted in patients with type 2 diabetes [7]. However among the 12 risk scores only two were
developed for stroke and neither had external validation [7]. So far, there have been no
prediction models developed for cerebrovascular disease in people with type 2 diabetes.
Furthermore there have been no models derived and validated to predict cerebrovascular
hospitalisation and re-hospitalisation in type 2 diabetes patients.

97	The objective of this study was to derive and externally validate new risk prediction algorithms
98	based on reliable ordinary clinical measurements recorded in primary care settings for
99	cerebrovascular hospitalisation within the following two years and cerebrovascular re-
100	hospitalisation within 90 days of a prior cerebrovascular hospitalisation.
101	
102	MATERIAL AND METHODS
103	Data setting and study population
104	Two prospective cohorts derived from Cambridgeshire, the United Kingdom were utilised in this
105	study. The derivation cohort included primary care electronic health record data and was used to
106	derive risk algorithms to predict cerebrovascular hospitalisation and re-hospitalisation. The
107	external validation cohort included post-trial data and was utilised to externally validate the two
108	risk algorithms.
109	Derivation cohort
110	The derivation cohort included type 2 diabetes patients registered in 18 general practices across
111	Cambridgeshire, England, in 2008/2009 with linkage to inpatient hospitalisation (Secondary Uses
112	Service (SUS)) data as part of a review of diabetes care across Cambridgeshire by the local health
113	board, National Health Service (NHS) Cambridgeshire. Egton Medical Information Systems (EMIS)
114	general practitioner (GP) software system was used in the cohort practices, from which a
115	predefined dataset could be extracted. No systematic selection process for these surgeries was
116	applied, and data extracted were for the whole diabetes population. The follow-up
117	hospitalisation data to 2010–2011 was available to all patients in the derivation cohort. Inpatient
118	hospitalisation to private and NHS hospitals within or outside Cambridgeshire were followed up.
119	Personal identifiers were not released to researchers, and only anonymized datasets were used
120	to conduct all subsequent analyses.

- 121 Validation cohort
  - 4

122 The validation cohort is a post-trial cohort derived from the RAndomized controlled trial of Peer Support in type 2 Diabetes (RAPSID) [8]. The design and research methods of the RAPSID have 123 been previously published [8]. In brief, RAPSID was designed as a 2x2 factorial cluster 124 125 randomized controlled trial comparing 4 arms: 1:1 peer support, group peer support, combined 126 support (1:1 plus group peer support) and control in patients with type 2 diabetes. All eligible 127 patients had their type 2 diabetes diagnosed for at least twelve months and those having 128 psychotic illness or dementia were ruled out. Patients were recruited from local communities 129 cross Cambridgeshire and its neighbouring areas of Hertfordshire and Essex. Post-trial follow-up 130 data were only available for patients residence in Cambridgeshire and its neighbouring areas of Hertfordshire that are served by the Cambridgeshire and Peterborough Clinical Commissioning 131 Group (CCG). The intervention was implemented following a pilot in a framework defined by 132 133 Peers for Progress [9]. The intervention duration was 8-12 months and was concluded between 2 134 June 2011 to 12 April 2012 [10, 11].

135

Demographic data, HbA1c, lipid profiles and blood pressure data were collected at baseline. Every
eligible patient was followed up till 30 June 2015 (0.91-4.07 years of follow-up from

138 beginning/entry date). Inpatient hospitalisation (NHS & private hospitals), Accident & Emergency

139 (A&E) and outpatient episodes within or outside Cambridgeshire and the included areas of

140 Hertfordshire were collected through Cambridgeshire and Peterborough Clinical CCG [12, 13] and

stored as the International Classification of Diseases (ICD-10) codes [14].

142

146

### 143 Definition of cerebrovascular hospitalisation and re-hospitalisation

The main outcomes in our study are cerebrovascular hospitalisation and rehospitalisation. The
 cerebrovascular hospitalisation was defined as having ≥1 hospitalisation with cerebrovascular

disease (CeVD) as the primary diagnosis (ICD-10: I60–I69 in the first ICD field) over the two-year

147 follow-up and cerebrovascular re-hospitalisation was defined as having ≥1 CeVD re-hospitalisation

148 within ninety days of prior CeVD hospitalisation.

### 149 Potential predictors, missing data, and power estimation

150 Objective clinical measurements including systolic and diastolic blood pressure, body mass index, glycated haemoglobin (HbA1c) and serum lipid profiles were used as predictors in the models to 151 facilitate the external application of the scores. Demographic characters, (sex and age) and 152 153 whether the patient was prescribed lipid-lowering medicine were also incorporated in our 154 models. In the UK primary care settings, diabetes patients were informed to have their blood pressure and metabolic measurements examined at least once a year since the date of diabetes 155 diagnosis and the most recent measurement was recorded before 1 April 2009 (giving a minimum 156 157 of fifty days before the first inpatient hospitalisation). The length of diabetes was not commonly 158 recorded, and therefore was not usefully accessible for the model derivation. The specific 159 treatment for diabetes and anti-hypertensive therapy were not accessible in this study. Lipid-

160 lowering prescription was recorded.

161

Missing information in the derivation cohort included body mass index (3.17%), systolic blood pressure (9.95%), diastolic blood pressure (9.95%), total cholesterol (12.35%), high-density lipoprotein cholesterol (14.56%), and low-density lipoprotein cholesterol (16.27%). Multiple imputation was used to replace missing values by applying a chained equation based on outcome and all potential predictors. 16 imputed datasets were generated for variables with missing values and were then combined over all imputed datasets by Rubin's rule to generate final prediction model estimations.

169

Few information was missing (<1%) in the external validation cohort and the complete dataset</li>
was used in the model validation. Based on 244 cerebrovascular inpatient hospitalisations and 95
cerebrovascular re-hospitalisations and 15 predictors or parameters in the development cohort,

173	an effective sample size (statistical power more than 80% [15]) of 16 cerebrovascular and 6
174	cerebrovascular re-hospitalisations per predictor or parameters was acquired.
175	

176 Ethical approval

177 Ethics approval was granted by the Cambridgeshire REC2 Committee (10/H0308/72), and patients

178 signed-off consent included their agreement for access to inpatient hospitalisation information.

179

#### 180 Model development and external validation

181 The incident cerebrovascular hospitalisation after the first ninety days of the incident occurrence

182 of cerebrovascular re-hospitalisation were treated as binary outcome. For each of the 15

183 candidate predictors or parameters, the Logistic regression was used to estimate the unadjusted

184 odds ratios. For model development, all candidate predictors were initially included in a

185 multivariable adjusted Logistic regression model. Fractional polynomials were utilised to model

186 non-linear relationships between continuous variables and outcomes.

187

188 Lowering lipid treatment was excluded from the multivariable Logistic regression model due to 189 its statistical insignificance (P>0.1 for log likelihood) through backward elimination. The 190 eliminated predictor was reinserted into the final prediction models to further examine whether 191 it changed to be statistically significant. Fractional polynomial parameters were also rechecked and re-estimated them if necessary. The risk algorithms were then formed for predicting the log 192 193 odds of cerebrovascular hospitalisation and cerebrovascular re-hospitalisation by using the 194 Logistic model regression coefficients multiplied by the parameters included in the models together with the intercept terms. This process generated equations for the predicted individual 195 risk=1/(1+e-riskscore), whether the "risk score" is the log odds of cerebrovascular hospitalisation 196 or cerebrovascular re-hospitalisation from the development models. 197

198

To facilitate risk score application in primary care, the equations were transferred into risk score charts. The coefficients from the logistic regression were multiplied by 50 and rounded to the nearest integer to generate the score per predictor. Multiplication by 50 was used as the majority of the coefficients was close to an integer, thereby minimizing the rounding effects. The total of prognostic scores indicates the patient probability of cerebrovascular hospitalisation or cerebrovascular re-hospitalisation.

205

206 The model performance in terms of the C-statistics and calibration slope (agreement between 207 observed and predicted risks, where 1.00 as ideal) was assessed. The C-statistics indicates the possibility that for any randomly sampled pair of diabetic patients with and without outcomes, 208 209 the patient with outcomes should have a higher predicted risk [16]. 0.50 of C-statistics indicates 210 no discrimination and 1.00 of calibration slope means perfect discrimination. Optimism (over-211 fitting) in model performance was corrected through internal validation by bootstrapping 100 212 samples of the development data. The model development process was then repeated in every 213 bootstrap data to generate a model, applied the model coefficient to the same bootstrap data to quantify apparent performance, and applied the model to the development dataset to examine 214 model performance (C-statistics and calibration slope) and optimism (difference between the 215 216 apparent and test performance). The overall optimism over all models was then estimated.

217

Our risk prediction models were applied to individual diabetic patient in the external validation
cohort dataset on the basis of the presence of one or more predictors. The final model
performance in external validation dataset in terms of discrimination by estimating the Cstatistics. We also evaluated model calibration by plotting agreement between observed and
predicted probability by decile of the predicted probability.

223

Stata V15.1 was used for all data analyses. We conducted and presented our study in line with the
Transparent Reporting of a multivariate prediction model for Individual Prognosis or Diagnosis
(TRIPOD) guidelines [17].

227

228 RESULTS

### 229 Characteristics of study participants

230 In the derivation dataset, information of 4,704 type 2 diabetes patients with 244 cerebrovascular

hospitalisations within two years and 95 re-hospitalisations within ninety days of a prior

232 cerebrovascular hospitalisation were analysed. The validation dataset incorporated information

233 of 1,121 diabetic patients with 56 cerebrovascular hospitalisations and 21 re-hospitalisations. The

234 baseline characteristics and candidate predictors of the cohorts are presented in Table-1. Patients

in both cohorts had similar distribution of gender, age, blood pressure and total cholesterol.

236 Patients in the development cohort dataset had a higher level of HbA1c, low-density lipoprotein

cholesterol, and high-density lipoprotein cholesterol. Compared with the development cohort

238 dataset, patients in the validation cohort dataset were more likely to take lowering-lipid medicine

and had more cerebrovascular hospitalisation and re-hospitalisation.

240

#### 241 Model development, performance, and validation

242 In the development dataset, the absolute risks of cerebrovascular hospitalisation within two

243 years and re-hospitalisation within 90 days post cerebrovascular hospitalisation were 3.76% and

244 1.46%, respectively. Associations between cerebrovascular hospitalisation and cerebrovascular re-

245 hospitalisation from univariable Logistic regression model are presented in Supplementary Table-

246

1.

247

Among the 10 potential predictors (15 parameters), 9 predictors (12 parameters) were

significantly associated with cerebrovascular hospitalisation and re-hospitalisation in our final risk

250	prediction model (Table-2). Table-3 presents apparent and internal validation model performance
251	measurements of the risk prediction model. After the adjustment of optimism, our final risk
252	prediction model was able to discriminate diabetic patients with and without cerebrovascular
253	hospitalisation with a C-statistics of 0.7509 (95% confidence interval 0.7436 to 0.7582), and
254	discriminate diabetic patients with and without cerebrovascular re-hospitalisation with a C-
255	statistics 0.7391 (0.7161 to 0.7451). The agreement between the observed and predicted
256	probability of outcomes showed good apparent calibrations (Top left of Figure-1 for
257	cerebrovascular hospitalisation and top right of Figure-1 for cerebrovascular re-hospitalisation).
258	The calibration slope with optimism adjustment was 0.9961 (0.9928 to 0.9995) and 0.9904
259	(0.9091 to 1.0525) for cerebrovascular hospitalisation and re-hospitalisation, respectively (Table-
260	3).
261	
262	External validation
263	In our external validation cohort dataset, the incidence of cerebrovascular hospitalisation and re-
264	hospitalisation were 4.99% and 1.87%, respectively. Applying the final models to our independent
265	external cohort gave a C-statistic of 0.7098 (0.6875 to 0.7321) for cerebrovascular hospitalisation
266	and 0.7184 (0.7041 to 0.7727) for cerebrovascular re-hospitalisation, and good calibration
267	(bottom left of Figure-1 for cerebrovascular hospitalisation and bottom right of Figure-1 for
268	cerebrovascular re-hospitalisation), with the calibration slope 0.9853 (0.9756 to 0.9966) and
269	0.9846 (0.8894 to 1.0796) for cerebrovascular hospitalisation and re-hospitalisation, respectively.
270	
271	Clinical examples
272	Supplementary Chart-1 presents a real clinical example of the application of risk prediction model
273	with graphical illustrations (risk score chart) for cerebrovascular hospitalisation and re-

hospitalisation and individual risk of re-hospitalisation within ninety days of a previouscerebrovascular hospitalisation.

277

### 278 DISCUSSION

279 Two new risk scores to quantify the individual absolute risk of cerebrovascular hospitalisation within two years and cerebrovascular re-hospitalisation after ninety days of prior cerebrovascular 280 281 hospitalisation in a prospective cohort of type 2 diabetes patients in English primary care settings 282 have been developed in this study. The two prediction models were validated externally in another independent prospectively English cohort. The two risk prediction scores revealed useful 283 discrimination and excellent calibration, with C-statistics of bigger than 0.70 both in our 284 285 derivation and external validation cohorts. The two risk prediction scores were derived from 286 routine clinical measurements recorded and accessible in primary care settings, indicating that 287 those can be applied in routine primary care (e.g. by embedding in practice software).

288

Kothari et al derived a prediction score to predict incident stroke within 10 years among 5,103
newly diagnosed type 2 diabetes patients in the UK Prospective Diabetes Study (UKPDS) [18].
Age, gender, atrial fibrillation, smoking, systolic blood pressure and lipid ratio were applied in the
final model as predictors. However, the model performance (either discrimination or calibration)
was not evaluated in the study. As the predictors like atrial fibrillation, duration of diabetes in the
UKPDS algorithm were not available in our cohorts, we could not validate the UKPDS in our
cohorts.

Yang et al derived a prediction model to predict incident stroke within 5 years among a Chinese
diabetes population [19]. The splitting sample method was applied to the total sample (7920 type
2 diabetes patients) to generate a derivation sample (3,652 patients) and a validation sample
(3,559 patients). The age, HbA1c, urinary albumin to creatinine ratio and history of coronary heart
disease were included in the final model as predicators. The apparent C-statistics in the derivation 11

sample was 0.78. And internal validated calibration suggested good. However, the splitting
method was not suggested in the derivation of prediction models and the external validation was
not implemented in this study. The source population in Yang's score was a Chinese population,
which is different from our population (Caucasian population). The data from Yang's score were
derived from a Diabetes registry (Hong Kong Diabetes Registry), which is different from our data
source (primary care data). And the predictor "history of CHD" was not available in our cohorts.
Therefore Yang's score could not be validated in our cohorts

308

309 Previous risk prediction models have not addressed cerebrovascular disease as a group as a 310 major reason and health cost for inpatient hospitalisation in type 2 diabetes patients. Being aware of the individual absolute risk of cerebrovascular hospitalisation in the following year, and 311 312 the risk of a new episode (within ninety days) of a recurrent cerebrovascular event (re-313 hospitalisation) could help clinicians to process more intensive care to patients with a high risk 314 profile and to decrease inpatient cost. Implementation approaches could be tested using a 315 randomized controlled trial format including embedding alerts into practice software and 316 increasing patient awareness of their risk.

317

There are several advantages in our two prediction models over those applied elsewhere. The two risk algorithms are on the basis of absolute risk derivation and validation in two prospective cohorts. Routine clinical measurements recorded in primary care settings were used to derive the two prediction models, which indicates that these measurements can be used straightforwardly in primary care and are modifiable for external validations in those developed countries that have primary care electronic health recorded dataset accessible for such objectives. The two scores can be readily imbedded into online tools for their application in primary care settings.

325

The approaches applied to develop and validate models are close to those models developed from the CPRD and QResearch studies [20, 21]. The predictors/parameters in the final scores are accurate and reliable clinical variables routinely recorded in general practices and routinely updated and reviewed for patients with type 2 diabetes, and are less varied than in other primary care electronic health record datasets. Moreover, the volume of missing values was relatively low, which would be less likely to lead to variation in potential external applications, although multiple imputation was applied.

333

We acknowledge that anti-diabetes treatments, diabetes duration, previous history of 334 cerebrovascular diseases, other type 2 diabetes complications (e.g. renal failure), anti-335 hypertensive treatments, lifestyle relevant predictors (like smoking), and comorbidities were not 336 337 taken into account due to limitations in our original data, but some prognostic factors were very 338 common in people with diabetes (like antihypertensive treatments which is 81.2% in patients with type 2 diabetes in the United Kingdom [22]) which would be less discriminated in the model and 339 340 we believe that the clinical measurements incorporated in the two prediction models could be proxies for inaccessible predictors. Data access limitations also barricaded extending the risk 341 prediction model to all diabetes complications rather than those relevant to cerebrovascular 342 343 hospitalisation. Due to the similarity between the development and validation cohort datasets, 344 further more independent external validation (e.g. external data from more developed 345 countries) are warranted.

346

To our knowledge, this is the 1st research to derive risk scores to quantify the two-year risk of
cerebrovascular hospitalisation and re-hospitalisation within ninety days of a prior
hospitalisation. For primary care practice these new two algorithms have two useful implications.
First, these models can be use as screening tools to identify patients with high probability of
cerebrovascular hospitalisation and re-hospitalisation. The two models are based on routine
13

352	accessible clinical information recorded in primary care settings and evaluated by diabetes care
353	teams. They can be imbedded into general practice computer systems or integrated into a
354	mobile application for a handheld mobile device for ease of utilisation. Secondly, the risk scores
355	could be applied to establish new thresholds of treatment in primary care practice through
356	consensus development of guidance.
357	
358	Conflict of interest
359	The authors declare that there is no conflict of interests with the publication of this paper.
360	
361	Acknowledgments
362	This work was supported by the National Institute for Health Research under its Research for
363	Patient Benefit (RfPB) Programme (Grant Reference Number PB-PG-0808-17303) and National
364	Institute for Health Research for Patient Benefit Programme (Ref PB-PG-0610-22311). The views
365	expressed are those of the authors and not necessarily those of the NHS, the NIHR or the
366	Department of Health.
367	We would like to thank Simon Cohn, Chris Bunn, Toby Prevost, Charlotte Paddison, Sarah Donald,
368	Candice Ward, Peers for Progress, West Anglia CLRN, Cambridgeshire & Peterborough PCT,
369	Primary Care Research Network – East of England, MRC Epidemiology Unit, Eastern Diabetes
370	Research Network, participating general practices, Jackie Williams, Caroline Taylor, Kym Mercer,
371	Kevin Baker, Ben Bowers, Kalsoom Akhter (CUH Wolfson Diabetes & Endocrinology Clinic), James
372	Brimicombe (Cambridge University), Kim Birch of Trumpington St General Practice, CUH Wolfson
373	Diabetes & Endocrinology Clinic Educators, The RAPSID Patient Committee (Phillip Jones, Liz
374	Carvlin, Roger Smith) and the peers and peer support participants.
375	

# 377 References

1. Emerging Risk Factors Collaboration, Sarwar, N, Gao, P, Seshasai, SR, Gobin, R, Kaptoge, S et al.

379 Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a

collaborative meta-analysis of 102 prospective studies. Lancet, 2010;9733:2215-2222.

2. Fox, CS, Coady, S, Sorlie, PD, D'Agostino RB, S, Pencina, MJ, Vasan, RS et al. Increasing

cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation,
 2007;12:1544-1550.

3. Authors/Task Force Members, Ryden, L, Grant, PJ, Anker, SD, Berne, C, Cosentino, F et al. ESC
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with
the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European
Society of Cardiology (ESC) and developed in collaboration with the European Association for the
Study of Diabetes (EASD). Eur. Heart J., 2013;39:3035-3087.

4. Sampson, MJ, Dozio, N, Ferguson, B, Dhatariya, K. Total and excess bed occupancy by age,
specialty and insulin use for nearly one million diabetes patients discharged from all English Acute
Hospitals. Diabetes Res. Clin. Pract., 2007;1:92-98.

392 5. Hatzitolios, AI, Didangelos, TP, Zantidis, AT, Tziomalos, K, Giannakoulas, GA, Karamitsos, DT.

- 393 Diabetes mellitus and cerebrovascular disease: which are the actual data?. J. Diabetes394 Complications., 2009;4:283-296.
- 395 6. Khalid, JM, Raluy-Callado, M, Curtis, BH, Boye, KS, Maguire, A, Reaney, M. Rates and risk of
- 396 hospitalisation among patients with type 2 diabetes: retrospective cohort study using the UK
- 397 General Practice Research Database linked to English Hospital Episode Statistics. Int. J. Clin.
- 398 Pract., 2014;1:40-48.

399 7. van Dieren, S, Beulens, JW, Kengne, AP, Peelen, LM, Rutten, GE, Woodward, M et al. Prediction
400 models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review.
401 Heart, 2012;5:360-369.


- 8. Simmons, D, Prevost, AT, Bunn, C, Holman, D, Parker, RA, Cohn, S et al. Impact of community
  based peer support in type 2 diabetes: a cluster randomised controlled trial of individual and/or
  group approaches. PLoS One, 2015;3:e0120277.
- 9. Simmons, D, Cohn, S, Bunn, C, Birch, K, Donald, S, Paddison, C et al. Testing a peer support
  intervention for people with type 2 diabetes: a pilot for a randomised controlled trial. BMC Fam.
  Pract., 2013:5-2296-14-5.
- 408 10. Xie, B, Ye, XL, Sun, ZL, Jia, M, Jin, H, Ju, CP et al. Peer support for patients with type 2 diabetes
  409 in rural communities of China: protocol for a cluster randomized controlled trial. BMC Public
  410 Health, 2014:747-2458-14-747.
- 411 11. Smith, SM, Paul, G, Kelly, A, Whitford, DL, O'Shea, E, O'Dowd, T. Peer support for patients with
  412 type 2 diabetes: cluster randomised controlled trial. BMJ, 2011:d715.

- 413 12. Simmons, D, Yu, D, Wenzel, H. Changes in hospital admissions and inpatient tariff associated
  414 with a Diabetes Integrated Care Initiative: preliminary findings. J. Diabetes, 2014;1:81-89.
- 415 13. Yu, D, Simmons, D. Association between pulse pressure and risk of hospital admissions for
  416 cardiovascular events among people with Type 2 diabetes: a population-based case-control
  417 study. Diabet. Med., 2015;9:1201-1206.
- 418 14. Yu, D, Simmons, D. Association between blood pressure and risk of cardiovascular hospital
  419 admissions among people with type 2 diabetes. Heart, 2014;18:1444-1449.
- 420 15. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox
  421 regression. Am J Epidemiol. 2007;165:710-8.
- 422 16. Yu, D, Simmons, D. Association between pulse pressure and risk of hospital admissions for
  423 cardiovascular events among people with Type 2 diabetes: a population-based case-control
  424 study. Diabet. Med., 2015;9:1201-1206.
- 425 17. Moons, KG, Altman, DG, Reitsma, JB, Ioannidis, JP, Macaskill, P, Steyerberg, EW et al.
- 426 Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis
- 427 (TRIPOD): explanation and elaboration. Ann. Intern. Med., 2015;1:W1-73.
- 428 18. Kothari, V, Stevens, RJ, Adler, Al, Stratton, IM, Manley, SE, Neil, HA et al. UKPDS 60: risk of
  429 stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke,
  430 2002;7:1776-1781.
- 431 19. Yang, X, So, WY, Kong, AP, Ho, CS, Lam, CW, Stevens, RJ et al. Development and validation of
  432 stroke risk equation for Hong Kong Chinese patients with type 2 diabetes: the Hong Kong
  433 Diabetes Registry. Diabetes Care, 2007;1:65-70.
- 434 20. Nwaru, BI, Simpson, CR, Sheikh, A, Kotz, D. External validation of a COPD prediction model
  435 using population-based primary care data: a nested case-control study. Sci. Rep., 2017:44702.
- 436 21. Hippisley-Cox, J, Coupland, C, Brindle, P. Development and validation of QRISK3 risk prediction
  437 algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ,
  438 2017;j2099.
- 439 22. Stone, MA, Charpentier, G, Doggen, K, Kuss, O, Lindblad, U, Kellner, C et al. Quality of care of
  440 people with type 2 diabetes in eight European countries: findings from the Guideline Adherence
  441 to Enhance Care (GUIDANCE) study. Diabetes Care, 2013;9:2628-2638.
- 442
- 443
- 444
- 445
- 446
- 447
- 16

### 448 FIGURE LEGENDS

449 **Figure-1**. Assessing calibration in the derivation cohort (left) and the validation cohort (right) for

450 cerebrovascular hospitalisation (above panel) and cerebrovascular re-hospitalisation (below451 panel)



# 452

### 453 **TABLES**

454 Table-1. Characteristics of study participants in development cohort and external validation455 cohort.

	Development cohort	Validation cohort
Number of participants	4,704	1,121
Cerebrovascular hospitalisation, n (%)	244 (3.76)	56 (4.99)
Cerebrovascular rehospitalisation, n (%)	95 (1.46)	21 (1.87)
Age a baseline, years	65.0±16.3	65.5±11.4
Female gender, n (%)	1,919 (40.8)	444 (39.6)
Systolic blood pressure, mmHg	134.5±16.0	139.7±20.2
Diastolic blood pressure, mmHg	76.3±10.0	75.5±11.5
Total cholesterol, mmol/L	4.3±1.2	4.2±1.7
High density lipoprotein cholesterol, mmol/L	1.3±0.6	1.1±1.2
Low density lipoprotein cholesterol, mmol/L	2.5±1.4	1.4±3.0
Body mass index, kg/m <sup>2</sup>	30.8±6.9	32.2±6.0
Glycated haemoglobin (HbA1c), mmol/mol / %	61.5±17.2 / 7.8±3.7	56.2±15.1/7.3±3.5

Taking lipid Lowering treatment, n (%)	3,342 (71.4)	731 (65.2)

**Table-2.** Multivariable model estimation for cerebrovascular hospitalisation and re-hospitalisation

458 risk among type 2 diabetes patients in development cohort

Predictors/Parameters	Coefficient	95% Confidence Interval			
Cerebrovascular Hospitalisation					
Male gender	0.3313	(0.2909 to 0.3716)			
Glycated haemoglobin (HbA1c) ≥ 57 mmol/mol (7.4%)	-0.1259	(-0.1638 to -0.0879)			
(Body mass index/10)^3	0.0624	(0.0520 to 0.0728)			
((Body mass index/10)^3)*In(Body mass index/10)	-0.0371	(-0.0435 to -0.0307)			
Systolic blood pressure/100	1.6098	(0.4821 to 2.7375)			
(Systolic blood pressure/100)^2	-0.2216	(-0.6220 to 0.1788)			
(Diastolic blood pressure/100)^-2	-0.0239	(-0.0483 to 0.0005)			
Diastolic blood pressure/100	-2.1136	(-2.3820 to -1.8452)			
(Total cholesterol/10)^-2	-0.0056	(-0.0079 to -0.0033)			
(Total cholesterol/10)^2	0.8866	(0.6862 to 1.0870)			
(High density lipoprotein cholesterol)^3	0.0851	(0.0563 to 0.1139)			
((High density lipoprotein cholesterol)^3)*In(High density lipoprotein cholesterol)	-0.0892	(-0.1192 to -0.0593)			
Low density lipoprotein cholesterol/10	-0.6356	(-0.9387 to -0.3325)			
(Low density lipoprotein cholesterol/10)^3	0.5521	(-0.2076 to 1.3117)			
Baseline age>=70 years	1.0647	(1.0213 to 1.1080)			
Constant	-4.7571	(-5.5717 to -3.9426)			
Cerebrovascular Re-hos	pitalisation				
Male gender	0.1359	(0.0741 to 0.1978)			
Glycated haemoglobin (HbA1c) ≥ 57 mmol/mol (7.4%)	-0.2318	(-0.2914 to -0.1722)			
(Body mass index/10)^3	0.0618	(0.0445 to 0.0792)			
((Body mass index/10)^3)*In(Body mass index/10)	-0.0383	(-0.0491 to -0.0274)			
Systolic blood pressure/100	-2.4341	(-3.7885 to -1.0798)			
(Systolic blood pressure/100)^2	1.2371	(0.7573 to 1.7169)			

(Diastolic blood pressure/100)^-2	0.6846	(0.4897 to 0.8794)
((Diastolic blood pressure/100)^-2)*In(Diastolic blood		
pressure/100)	0.3780	(0.2058 to 0.5501)
(Total cholesterol/10)^3	-1.4790	(-2.3056 to -0.6524)
((Total cholesterol/10)^3)*In(Total cholesterol/10)	-11.2187	(-13.7345 to -8.7029)
(High density lipoprotein cholesterol)^3	0.1949	(0.1535 to 0.2362)
((High density lipoprotein cholesterol)^3)*In(High		
density lipoprotein cholesterol)	-0.1992	(-0.2412 to -0.1572)
Low density lipoprotein cholesterol/10	0.0291	(-0.4999 to 0.5582)
(Low density lipoprotein cholesterol/10)^3	-1.6879	(-3.0975 to -0.2784)
Baseline age>=70 years	1.1117	(1.0424 to 1.1811)
Constant	-6.2027	(-7.2062 to -5.1991)

**Table-3.** Model performance statistics (with 95% confidence interval)

Measure	Apparent performance	Test performance	Average optimism	Optimism corrected performance	External validation	
	Cerebrovascular Hospitalisation					
C-statistic	1.0000 (0.9967 to 1.0034)	0.9961 (0.9884 to 1.0038)	0.0039	0.9961 (0.9928 to 0.9995)	0.9853 (0.9756 to 0.9966)	
Calibration slope	0.7546 (0.7473 to 0.7619)	0.7509 (0.7454 to 0.7564)	0.0037	0.7509 (0.7436 to 0.7582)	0.7098 (0.6875 to 0.7321)	
	Cerebrovascular Re-hospitalisation					
C-statistic	1.0000 (0.9557 to 1.0443)	0.9904 (0.9187 to 1.0621)	0.0096	0.9904 (0.9091 to 1.0525)	0.9846 (0.8894 to 1.0796)	
Calibration slope	0.7476 (0.7403 to 0.7549)	0.7391 (0.7246 to 0.7536)	0.0085	0.7391 (0.7161 to 0.7451)	0.7184 (0.7041 to 0.7327)	